TITLE

Plenty of green in gray market

AUTHOR(S)
MAY, DAVID
PUB. DATE
October 2011
SOURCE
Modern Healthcare;10/17/2011, Vol. 41 Issue 42, p25
SOURCE TYPE
Trade Publication
DOC. TYPE
Editorial
ABSTRACT
The author asserts that as providers are confronting shortages of drugs of all types, including chemotherapy agents, they have become increasingly troubled by the increasing costs. He says that the problems are attributed to companies responsible for creating and perpetuating the drug shortages. He notes that an inventory is readily available if providers turn to secondary distributors but profit markups are high.
ACCESSION #
66965808

 

Related Articles

  • Health Council urges national program on pharmaceuticals.  // CCPA Monitor;Mar2009, Vol. 15 Issue 9, p39 

    The article reports that the Health Council of Canada is urging all governments in Canada to establish national programs on pharmaceuticals. The council asserts that more Canadians will need help with the high costs of prescription drugs in the wake of the tough economy. Canadians are claimed to...

  • Drug Companies Are Top Health Care Lobbyists; Study Suggests Declining Political Influence of Physicians.  // Ascribe Newswire: Medicine;4/6/2004, p16 

    Pharmaceutical companies spend more money lobbying the U.S. Congress than other health care organizations, according to a new study in the April 1, 2004, issue of the "American Journal of Medicine." Among health care organizations, drug companies spent the most on lobbying, $96 million, followed...

  • What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries. Gemmill, Marin C.; Thomson, Sarah; Mossialos, Elias // International Journal for Equity in Health;2008, Vol. 7, Special section p1 

    As pharmaceutical expenditure continues to rise, third-party payers in most high-income countries have increasingly shifted the burden of payment for prescription drugs to patients. A large body of literature has examined the relationship between prescription charges and outcomes such as...

  • Forum.  // Pharmaceutical Medicine - New Zealand;Feb2016, Vol. 30 Issue 1, p57 

    This section offers news briefs on the pharmaceutical industry as of February 2016. These include the publication of the interim report for the UK Accelerated Access Review, which is aimed at enabling more rapid access to innovative treatments in Great Britain, the launch of a campaign targeting...

  • Drug Licenses: A New Model For Pharmaceutical Pricing. Goldman, Dana P.; Jena, Anupam B.; Philipson, Tomas; Sun, Eric // Health Affairs;Jan/Feb2008, Vol. 27 Issue 1, p122 

    High drug prices are a major barrier to patients' access to drugs and compliance with treatment. Yet low drug prices are often argued to provide inadequate incentives for innovation. We propose a drug-licensing model for health care, which has the promise of increasing drug use without altering...

  • PHARMACEUTICAL STRESS FROM FRAUD AND DECEIT.  // Health & Stress;Mar2008, Issue 3, p1 

    The article focuses on how large pharmaceutical companies have brought disturbance in their quest for higher revenues that have made them the most profitable industry in the U.S. The drugs' inflation rate was cited as the main reason for the increase of health costs and insurance payments....

  • Do Well by Doing Good. Katen, Karen // Leadership Excellence Essentials;Oct2006, Vol. 23 Issue 10, p6 

    The article discusses ethical issues in the pharmaceutical industry. It addresses the effect of business purpose and higher mission on morals. Problems concerning profit motive in the industry are addressed. Moreover, the impact of profit on the pharmaceutical industry is tackled. The role of...

  • Demand for drug imports rises. Bloice, Carl // Revolution: The Journal for RNs & Patient Advocacy;Mar/Apr2004, Vol. 5 Issue 2, p8 

    Discusses the rise in the demand for drug imports in the United States. Prescription drug costs; Drug import safety; Safety systems for importing drugs.

  • Availability and affordability of new medicines in Latin American countries where pivotal clinical trials were conducted. Homedes, NĂºria; Ugalde, Antonio // Bulletin of the World Health Organization;Oct2015, Vol. 93 Issue 10, p674 

    Objective To assess whether new pharmaceutical products approved by the United States Food and Drug Administration (FDA) in 2011 and 2012 were registered, commercialized and sold at affordable prices in the Latin American countries where they were tested. Methods We obtained a list of new...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics